# V1 Empirics Check — deepseek/deepseek-v3.2 (Variant A)

**Model:** deepseek/deepseek-v3.2
**Variant:** A
**Date:** 2026-03-27T14:17:01.251196

---

**Referee Report:** "The Detection Dividend: Drug-Type Decomposition of Fentanyl Test Strip Effects on Overdose Mortality"

**1. Idea Fidelity**

The paper faithfully pursues the core idea outlined in the original manifest. It correctly implements the proposed triple-difference (DDD) design, contrasting high-contamination (heroin, cocaine) and low-contamination (methadone, natural opioids) drugs across states and over time to test the information-revelation mechanism of Fentanyl Test Strip (FTS) legalization. The data source (CDC VSRR) and primary empirical framework align with the manifest.

However, the paper deviates from the manifest in one significant way. The manifest explicitly lists "synthetic opioids (T40.4)" as a high-contamination drug type for the decomposition. The paper instead excludes synthetic opioids from its main DDD specification, arguing that using "fentanyl deaths as an outcome for a fentanyl-detection intervention introduces a mechanical correlation." This is a consequential analytical choice that requires much stronger justification, as it removes a primary outcome of interest from the main test.

**2. Summary**

This paper employs a novel triple-difference design to test whether the legalization of fentanyl test strips reduces overdose deaths by providing users with information about fentanyl contamination. By comparing trends between high- and low-contamination risk drugs across legalizing and non-legalizing states, the study finds a negative but statistically insignificant DDD estimate. A key ancillary finding is a significant *increase* in methadone deaths post-legalization, which the authors interpret as evidence of confounding from correlated expansions in harm-reduction services.

**3. Essential Points (Must Address)**

The paper requires major revisions to establish a credible causal claim. The current evidence is insufficient for publication.

**1. The Exclusion of Synthetic Opioid Deaths Undermines the Proposed Mechanism Test.**
The theoretical mechanism is that FTS reveal *fentanyl* contamination. The most direct outcome for this test is deaths involving synthetic opioids (primarily fentanyl). The paper’s decision to exclude T40.4 because it is "the outcome for a fentanyl-detection intervention" is conceptually flawed. If FTS work, they should reduce deaths where fentanyl is present—which is precisely what the T40.4 code captures. The concern about a "mechanical correlation" is unclear. The identification comes from the *differential* effect on high vs. low-contamination drugs, not the aggregate level. The manifest's approach—including synthetic opioids as a high-contamination category—is more logical. The authors must either include synthetic opioids in their main DDD or provide a far more rigorous, theoretical econometric argument for their exclusion. As is, the test is incomplete.

**2. The "Methadone Negative Control" Result Indicates a Critical Violation of the Parallel Trends Assumption.**
The DDD design relies on the assumption that, absent treatment, the *gap* in death trends between high- and low-contamination drugs would evolve similarly in treated and control states. The significant positive effect on methadone deaths in treated states strongly suggests this assumption is violated. The authors correctly note this likely signals confounding (e.g., simultaneous expansion of medication-assisted treatment). However, they do not adequately address the implications: this confound likely **also differentially affects the high-contamination drugs** (e.g., heroin deaths may fall due to increased methadone treatment access, not FTS). The DDD coefficient is therefore biased. The authors must:
   a) Formally test the parallel trends assumption for the DDD, perhaps via an event study or leads-and-lags model.
   b) Actively control for other major, concurrent harm-reduction policies (e.g., naloxone access laws, Good Samaritan laws, syringe service program expansions) in their DDD specification. Simply noting the confound is insufficient; they must test robustness to its inclusion.

**3. Data Construction and Power Issues Threaten the Interpretation of "Null" Results.**
   a) **Aggregation Choice:** Aggregating monthly data to state-year-drug cells loses substantial variation and may mask short-term dynamics following legalization. The justification (reducing suppression) is practical, but the authors must demonstrate their results are robust to using more granular data (e.g., state-quarter-drug) where feasible.
   b) **Statistical Power:** With only 9 years of data, heavily staggered adoption, and noisy, low-count outcomes for specific drugs in some state-years, the study may be severely underpowered. The wide confidence intervals support this. The authors should conduct a post-hoc power analysis or, better, use their research design and data to simulate the Minimum Detectable Effect (MDE). This is crucial for interpreting the null result: is the effect truly zero, or is the test simply incapable of detecting a plausible effect size?

**4. Suggestions**

*Refine the Drug-Type Classification and Analysis:*
1.  **Re-integrate Synthetic Opioids:** Follow the manifest. Run the main DDD with synthetic opioids classified as "high-contamination." Present this as the primary specification and relegate the current version to a robustness check. Discuss the interpretation: a reduction in synthetic opioid-involved deaths for heroin/cocaine would be strong evidence for the mechanism.
2.  **Analyze Psychostimulants More Thoroughly:** The manifest listed psychostimulants (T43.6) as a drug type. The paper uses it only as a "placebo." Given emerging evidence of fentanyl contamination in methamphetamine markets, this category may represent an interesting intermediate or evolving risk group. A separate analysis of this category could be informative.
3.  **Address Multiple Counting:** The paper notes deaths can have multiple drug codes. This creates a dependency across drug-type observations within a state-year that isn't fully absorbed by state-year FEs. Consider sensitivity checks using: (i) mutually exclusive categories (e.g., deaths involving *only* heroin), or (ii) a multinomial model at the death-count level (if micro-data can be accessed).

*Strengthen Empirical Design and Robustness:*
4.  **Implement an Event-Study DDD:** Replace the static `Post × HighContam` variable with a series of leads and lags (e.g., `Legalize[k] × HighContam` for k years before/after). This is the standard test for parallel pre-trends in a staggered DDD and would directly address Essential Point #2.
5.  **Control for Policy Bundles:** Collect data on other major drug policies enacted in the same period. Include them as controls in a saturated DDD model (e.g., `Post × HighContam × Policy` interactions) or show results are stable when adding them as covariates. This is critical for isolating the FTS effect.
6.  **Consider Alternative Estimators:** Given the staggered adoption and potential for heterogeneous treatment effects, discuss the applicability of estimators like Callaway and Sant'Anna (2021) or Sun and Abraham (2021) for the DDD context. At minimum, show that the two-way fixed effects estimator is not heavily biased by negative weights (e.g., calculate the `did` package's weight distribution).

*Improve Narrative and Presentation:*
7.  **Reframe the Contribution:** The paper's most compelling contribution may not be the null DDD result, but the **methodological demonstration** of how a negative control (methadone) can reveal confounding in policy evaluation. Lean into this. The title and abstract could better highlight this diagnostic insight.
8.  **Clarify the "Fentanyl Saturation" Argument:** The introduction mentions this as a reason for prior null findings. Use this to frame your heterogeneity analysis. Test if effects are larger in states that legalized earlier (pre-2020) versus later, when saturation was presumably lower.
9.  **Improve Table and Visualization:** `Table 2` (drug-specific effects) is confusing as presented. It shows simple DiD estimates without the DDD differencing. Instead, present the DDD coefficients from a fully interacted model (i.e., the coefficients on `Post × DrugType` for each drug, relative to a base category). Also, include a graphical event-study plot for the DDD.
10. **Tighten the Discussion:** The discussion section is somewhat speculative. Ground it more firmly in the specific results. For example, instead of generally mentioning "bundling," state: "Our finding of increased methadone deaths coincident with FTS legalization suggests that the `Post` indicator captures, on average, a 2.3/100k increase from correlated MAT expansion. This implies our DDD estimate may be biased upward (less negative) by approximately X amount."

*Data and Reproducibility:*
11. **Provide Explicit Data Code:** The appendix should include the exact API call and processing code to recreate the panel from the CDC VSRR. Given the non-standard aggregation (state-year-drug from monthly data), this is vital.
12. **Report Sample Sizes Clearly:** The manifest mentioned 50 states x 120 months x 6 drug types. The paper's N=1,581 state-year-drug observations seems low. Provide a clear accounting of the sample selection process (how many state-drug-years dropped due to <6 months of data?).

**Overall Recommendation:** Revise and Resubmit. The paper tackles an important, timely question with a clever design. However, the current execution has significant flaws in its empirical specification (exclusion of key outcomes, unaddressed confounding) that preclude a credible causal interpretation. Addressing the essential points, particularly by including synthetic opioids and rigorously testing for parallel trends, could make this a valuable contribution.
